Pharma Mar Overview
Update this profile
Share Price
$67.41
(As of Thursday Closing)
Pharma Mar General Information
Description
Pharma Mar SA is engaged in the research, development, production, and commercialization of bio-active principles of marine origin for application in oncology. It also produces and market insecticides and air fresheners for household use, household products, wood treatment and decoration products, paints, and similar products. Its operating business segments are Oncology, Diagnostics, Consumer chemicals, and RNAi. The company obtains its revenues from two main areas: biopharmaceuticals and consumer chemicals, but the biopharmaceuticals is the main line of business.
Contact Information
Want to dig into this profile?
We’ll help you find what you need
Learn more
Pharma Mar Stock Performance
(As of Thursday Closing)
Stock Price
Previous Close
52 wk Range
Market Cap
Shares
Average Volume
EPS
$67.41
$68.14
$52.56 - $98.41
$1.21B
18M
63.2K
$5.84
Pharma Mar Financials Summary
In Thousands, USD
TTM
31-Mar-2022
FY 2021
31-Dec-2021
FY 2020
31-Dec-2020
FY 2019
31-Dec-2019
EV
1,202,658
978,458
1,424,746
949,099
Revenue
269,183
271,729
307,732
96,070
EBITDA
121,703
122,622
177,376
(10,934)
Net Income
105,293
109,787
156,467
(12,738)
Total Assets
421,925
417,094
406,208
139,691
Total Debt
53,236
55,856
69,696
96,464
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Pharma Mar Valuation & Funding
Deal Type
Date
Amount
Valuation/ EBITDA
Post-Val
Status
Debt
This information is available in the PitchBook Platform. To explore Pharma Mar‘s full profile, request access.
Request a free trial
Pharma Mar Patents
938
Total Documents
Applications and Grants
000
Total Patents
Families
12
Granted
2
Pending
000
Expiring
in next 12 mo
Pharma Mar Recent Patent Activity
Publication ID
Patent Title
Status
First Filing Date
Technology (CPC)
Citations
CA-3123744-A1
Anticancer compounds
Pending
17-Dec-2018
0000000000
AU-2019400736-A1
Anticancer compounds
Pending
17-Dec-2018
0000000000
EP-3898613-A1
Anticancer compounds
Pending
17-Dec-2018
0000000000
CA-3117268-A1
Antibody drug conjugates comprising ecteinascidin derivatives
Pending
25-Oct-2018
00000000000
AU-2019368687-A1
Antibody drug conjugates comprising ecteinascidin derivatives
Pending
25-Oct-2018
A61K47/6803
To view Pharma Mar’s complete patent history, request access »
Pharma Mar Executive Team (8)
Update this profile
Name
Title
Board Seat
Contact Info
José Sousa-Faro Ph.D
Board Member & Chief Executive Officer
Maria de Francia Caballero
Chief Financial Officer
Pascal Besman
Chief Operating Officer
José Martinez-Losa
Director, Capital Markets & Investor Relations
María Marín de la Plaza
Capital Markets & Investor Relations
You’re viewing 5 of 8 executive team members. Get the full list »
Pharma Mar Signals
Growth Rate
0.80%
Weekly Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trial
Pharma Mar Investors
Investor Name
Investor Type
Holding
Investor Since
Participating Rounds
Contact Info
This information is available in the PitchBook Platform. To explore Pharma Mar‘s full profile, request access.
Request a free trial